HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment

Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mengting, Liu, Yaxin, Shao, Bin, Liu, Xiaoran, Hu, Zhiyuan, Wang, Chen, Li, Huiping, Zhu, Ling, Li, Ping, Yang, Yanlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554095/
https://www.ncbi.nlm.nih.gov/pubmed/36246381
http://dx.doi.org/10.3389/fbioe.2022.1015295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554095/
https://www.ncbi.nlm.nih.gov/pubmed/36246381
http://dx.doi.org/10.3389/fbioe.2022.1015295

Ejemplares similares